CLL / SLL

30 clinical trials · Condition

Record	Firm	Date
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL (NCT05365100)	BioNova Pharmaceuticals (Shanghai) LTD.	2022-07-01
Early Intervention With Acalabrutinib in Patients With High Risk CLL (NCT04660045)	Weill Medical College of Cornell University	2022-05-01
A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies (NCT05269940)	Nanjing Zenshine Pharmaceuticals	2022-02-17
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (NCT05176691)	Hutchmed	2022-02-15
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. (NCT04775745)	Newave Pharmaceutical Inc	2021-07-19
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy (NCT04149821)	Weill Medical College of Cornell University	2021-02-10
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) (NCT04523428)	Stichting Hemato-Oncologie voor Volwassenen Nederland	2020-12-23
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT04694560)	Memorial Sloan Kettering Cancer Center	2020-12-22
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL (NCT04215809)	Ascentage Pharma Group Inc.	2020-03-02
A Study to Evaluate ICP-022 in Patients With CLL/ SLL (NCT03493217)	Beijing InnoCare Pharma Tech Co., Ltd.	2018-04-17
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies (NCT00714259)	University of Alabama at Birmingham	2008-07-01

Track CLL / SLL automatically

Every clearance here is in the API, with alerts when new ones post.